Effectiveness, weight changes and metabolic outcomes on switch to generic dolutegravir/lamivudine amongst people with HIV in Western India: An observational study.

Switching to Dolutegravir/Lamivudine: A New Path in the HIV Desert

HIV, a chronic viral infection that weakens the immune system, presents a lifelong challenge for those living with it. However, advances in antiretroviral therapy (ART) have dramatically improved the lives of people with HIV. This research investigates the effectiveness and safety of switching to a specific ART regimen, dolutegravir/lamivudine (DTG/3TC), in a group of people living with HIV (PWH) in Western India.

DTG/3TC: A New Oasis in the HIV Desert?

This study followed 304 PWH who switched to DTG/3TC for a median of 40 weeks. The results were encouraging: no virologic failures were observed, and the rates of virologic suppression remained high over the study period. The authors also observed a significant weight gain associated with switching to DTG/3TC, particularly among those who previously received a specific ART regimen.

DTG/3TC: Navigating the Landscape of Side Effects

The research also assessed the safety of switching to DTG/3TC, finding that it was generally well-tolerated. While a trend towards worsening hyperglycemia was noted, no clinically significant changes in lipids or kidney function were documented. This suggests that DTG/3TC may be a safe and effective option for many PWH, particularly those with a high burden of co-morbidities.

Dr. Camel's Conclusion

This research provides valuable information on the effectiveness and safety of switching to DTG/3TC in a real-world setting. The findings suggest that DTG/3TC may be a promising option for PWH in India, particularly those seeking a safe and effective ART regimen with potential benefits for weight gain and overall health. However, further research is needed to understand the long-term effects of DTG/3TC in different populations.